Citi analyst Yigal Nochomovitz started Unity Biotechnology with a Buy rating and $32 price target. The company is developing a novel class of potentially transformative drugs aimed at extending human healthspan, Nochomovitz tells investors in a research note. The analyst views Unity as a leader in the senescence field
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.